Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 8,040,000 shares, a decrease of 24.9% from the June 30th total of 10,700,000 shares. Based on an average daily volume of 1,830,000 shares, the days-to-cover ratio is presently 4.4 days.
Insider Transactions at Atara Biotherapeutics
In other news, CEO Pascal Touchon sold 14,220 shares of the stock in a transaction on Monday, June 27th. The stock was sold at an average price of $7.20, for a total transaction of $102,384.00. Following the completion of the transaction, the chief executive officer now directly owns 472,093 shares in the company, valued at approximately $3,399,069.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO Utpal Koppikar sold 5,582 shares of the firm’s stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $5.32, for a total transaction of $29,696.24. Following the completion of the transaction, the chief financial officer now directly owns 207,592 shares in the company, valued at approximately $1,104,389.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Pascal Touchon sold 14,220 shares of the firm’s stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $7.20, for a total value of $102,384.00. Following the transaction, the chief executive officer now owns 472,093 shares of the company’s stock, valued at $3,399,069.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,811 shares of company stock worth $243,848. 4.00% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd increased its position in Atara Biotherapeutics by 343.8% during the first quarter. Point72 Hong Kong Ltd now owns 7,234 shares of the biotechnology company’s stock worth $67,000 after buying an additional 5,604 shares during the period. Running Point Capital Advisors LLC acquired a new position in Atara Biotherapeutics during the first quarter worth approximately $93,000. Monashee Investment Management LLC acquired a new position in Atara Biotherapeutics during the first quarter worth approximately $93,000. Envestnet Asset Management Inc. acquired a new position in Atara Biotherapeutics during the first quarter worth approximately $112,000. Finally, Teacher Retirement System of Texas increased its position in Atara Biotherapeutics by 12.6% during the first quarter. Teacher Retirement System of Texas now owns 15,447 shares of the biotechnology company’s stock worth $144,000 after buying an additional 1,728 shares during the period.
Wall Street Analyst Weigh In
Atara Biotherapeutics Price Performance
Shares of NASDAQ ATRA opened at $2.85 on Tuesday. Atara Biotherapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $20.04. The stock’s 50-day simple moving average is $5.55 and its 200-day simple moving average is $8.59.
Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) last issued its earnings results on Thursday, May 5th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.11. Atara Biotherapeutics had a negative return on equity of 122.18% and a negative net margin of 1,451.79%. The business had revenue of $7.31 million for the quarter, compared to analyst estimates of $6.58 million. During the same quarter last year, the company earned ($0.86) EPS. As a group, research analysts predict that Atara Biotherapeutics will post -3.43 earnings per share for the current fiscal year.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.
- Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook Brightens
- Deep Value High Yield Newell Brands Is Ready To Bottom
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.